TREATMENT OF CHRONIC NONVALVULAR ATRIAL-FIBRILLATION IN THE ELDERLY - A DECISION-ANALYSIS

被引:63
作者
NAGLIE, IG
DETSKY, AS
机构
[1] TORONTO HOSP,DIV CLIN EPIDEMIOL,TORONTO,ONTARIO,CANADA
[2] TORONTO HOSP,CLIN EPIDEMIOL UNIT,TORONTO,ONTARIO,CANADA
[3] UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA
[4] UNIV TORONTO,DEPT HLTH ADM,TORONTO M5S 1A1,ONTARIO,CANADA
[5] TORONTO HOSP,DIV GEN INTERNAL MED,TORONTO,ONTARIO,CANADA
[6] TORONTO HOSP,DIV GERIATR MED,TORONTO,ONTARIO,CANADA
关键词
CHRONIC ATRIAL FIBRILLATION; ELDERLY; ANTICOAGULATION; WARFARIN; ASPIRIN; DECISION ANALYSIS; MARKOV ANALYSIS; QUALITY OF LIFE;
D O I
10.1177/0272989X9201200401
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The objective of the study was to determine the preferred treatment strategy for elderly patients with chronic nonvalvular atrial fibrillation (CNVAF). A Markov decision-analytic model was used to compare three treatment strategies for CNVAF: 1) warfarin; 2) aspirin; and 3) no treatment. Five-year quality-adjusted life years (QALYs) were calculated for male and female cohorts aged 70 and 75 years, In the baseline analysis (effectiveness of warfarin 0.70, effectiveness of aspirin = 0.45, utility of warfarin 0.99, and utility of aspirin = 0.999) the quality-adjusted survival rates for 70-year-old males were 4.03 QALYs on warfarin, 4.02 QALYs on aspirin, and 3.95 QALYs on no treatment. Results were similar for all age and sex cohorts. Sensitivity analyses revealed that the results were very sensitive to the effectiveness of aspirin and the disutility of warfarin. The authors conclude that the optimal strategy for the treatment of CNVAF in elderly patients varies with the disutility assigned to warfarin therapy and the effectiveness value for aspirin therapy.
引用
收藏
页码:239 / 249
页数:11
相关论文
共 37 条
[1]  
Beck J R, 1981, Med Decis Making, V1, P285, DOI 10.1177/0272989X8100100309
[2]   THE MARKOV PROCESS IN MEDICAL PROGNOSIS [J].
BECK, JR ;
PAUKER, SG .
MEDICAL DECISION MAKING, 1983, 3 (04) :419-458
[3]   RISK FOR SYSTEMIC EMBOLIZATION OF ATRIAL-FIBRILLATION WITHOUT MITRAL-STENOSIS [J].
CABIN, HS ;
CLUBB, KS ;
HALL, C ;
PERLMUTTER, RA ;
FEINSTEIN, AR .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 65 (16) :1112-1116
[4]  
CAMPBELL A, 1974, BRIT HEART J, V36, P1005
[5]   CANADIAN ATRIAL-FIBRILLATION ANTICOAGULATION (CAFA) STUDY [J].
CONNOLLY, SJ ;
LAUPACIS, A ;
GENT, M ;
ROBERTS, RS ;
CAIRNS, JA ;
JOYNER, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (02) :349-355
[6]   ANTITHROMBOTIC THERAPY IN ATRIAL-FIBRILLATION [J].
DUNN, M ;
ALEXANDER, J ;
DESILVA, R ;
HILDNER, F .
CHEST, 1989, 95 (02) :S118-S127
[7]  
DUNN M, 1986, CHEST S, V89, P685
[8]  
FISHER CM, 1979, GERIATRICS, V34, P59
[9]  
FLEGEL KM, 1987, LANCET, V1, P526
[10]  
GAJEWSKI J, 1981, JAMA-J AM MED ASSOC, V245, P1540